Allogene Therapeutics, Inc.
ALLO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001737287
In the last 90 days, Allogene Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 209 institutions reported holding it in 13F filings for Q2 2026, worth $652.0M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Allogene Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 1 filing
- 1 insider, $63.0K in total
- Insiders trading
- 1
- Net value
- −$63.0K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Allogene Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Douglas Earl Martin | SVP, General Counsel | 488,267 | Aug 25, 2026 | 2 |
| Roberts Zachary | President and CEO | 581,166 | Jul 6, 2026 | 3 |
| Sato Vicki L | Director | 162,575 | Jun 23, 2026 | 1 |
| Kazam Joshua A | Director | 398,463 | Jun 23, 2026 | 2 |
| Humer Franz B | Director | 307,507 | Jun 23, 2026 | 1 |
| Witte Owen N. | Director | 292,832 | Jun 23, 2026 | 1 |
| Messemer Deborah M. | Director | 107,431 | Jun 23, 2026 | 1 |
| Barrett Elizabeth A. | Director | – | Jun 23, 2026 | 1 |
| Mayo Stephen | Director | 25,328 | Jun 23, 2026 | 1 |
| Yoshiyama Annie | SVP, Finance | 124,517 | Apr 23, 2026 | 2 |
| Beneski Benjamin Machinas | SVP, Chief Technical Officer | 195,338 | Apr 2, 2026 | 5 |
| Chang David D | President and CEO | 5,150,599 | Mar 18, 2026 | 2 |
| Belldegrun Arie | Director | 2,236,816 | Feb 4, 2026 | 1 |
| Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | 1,252,795 | Feb 4, 2026 | 2 |
| Moore Timothy L. | Chief Technical Officer | 250,713 | Feb 5, 2025 | 0 |
| Chen Yinlin Jack | SVP, Finance | 88,881 | Aug 14, 2023 | 0 |
| Smith Lillian | VP, Corporate Counsel | 140,390 | Apr 5, 2023 | 0 |
| Schmidt Eric Thomas | Chief Financial Officer | 862,439 | Mar 24, 2023 | 0 |
| Moore Alison | Chief Technical Officer | 672,731 | Mar 24, 2023 | 0 |
| Bhavnagri Veer | General Counsel | 556,049 | Mar 16, 2023 | 0 |
| Amado Rafael | EVP of R&D | 541,946 | Oct 11, 2022 | 0 |
| PF Equity Holdings 2 B.V. | 10% Owner | 0 | Apr 4, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 4, 2026 (view filing) | Feb 2 | 2 days | Beneski Benjamin MachinasSVP, Chief Technical Officer | SSale | −7.55K | $1.73 | −$13.1K | −3.5%210.2K after | |
| Mar 4, 2026 (view filing) | Mar 2 | 2 days | Beneski Benjamin MachinasSVP, Chief Technical Officer | SSale | −7.13K | $2.60 | −$18.5K | −3.4%203.0K after | |
| Mar 18, 2026 (view filing) | Mar 16 | 2 days | Chang David DPresident and CEO | SSale | −47.8K | $2.47 | −$118.0K | −0.9%5.15M after | |
| Mar 18, 2026 (view filing) | Mar 16 | 2 days | Beneski Benjamin MachinasSVP, Chief Technical Officer | SSale | −4.83K | $2.47 | −$11.9K | −2.4%198.2K after | |
| Apr 2, 2026 (view filing) | Mar 31 | 2 days | Beneski Benjamin MachinasSVP, Chief Technical Officer | SSale | −2.87K | $2.50 | −$7.17K | −1.4%195.3K after | |
| Apr 23, 2026 (view filing) | Apr 21 | 2 days | Yoshiyama AnnieSVP, Finance | SSale | −9.59K | $2.31 | −$22.1K | −7.1%124.5K after | |
| Aug 25, 2026 (view filing)4:43 PM ET | Aug 21 | 4 days | Douglas Earl MartinSVP, General Counsel | SSale | −29.7K | $2.12 | −$63.0K | −5.7%488.3K after |